252 related articles for article (PubMed ID: 20433602)
1. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
3. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
4. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
5. Itraconazole may increase the risk of early-onset bortezomib-induced peripheral neuropathy.
Hashimoto N; Yokoyama K; Sadahira K; Ueda T; Tsukada Y; Okamoto S
Int J Hematol; 2012 Dec; 96(6):758-63. PubMed ID: 23179905
[TBL] [Abstract][Full Text] [Related]
6. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology].
Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ;
Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470
[TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
8. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
9. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in combination with conventional chemotherapeutic agents for multiple myeloma compared with bortezomib alone.
Min CK; Lee MJ; Eom KS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Lim J; Kim Y; Han K
Jpn J Clin Oncol; 2007 Dec; 37(12):961-8. PubMed ID: 18156171
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
12. General aspects and mechanisms of peripheral neuropathy associated with bortezomib in patients with newly diagnosed multiple myeloma.
Broyl A; Jongen JL; Sonneveld P
Semin Hematol; 2012 Jul; 49(3):249-57. PubMed ID: 22726548
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib in multiple myeloma.
Meisler AI
N Engl J Med; 2003 Sep; 349(13):1287-8; author reply 1287-8. PubMed ID: 14510013
[No Abstract] [Full Text] [Related]
14. Bortezomib-induced peripheral neuropathy in patients with multiple myeloma.
Berkowitz A; Walker S
Clin J Oncol Nurs; 2012 Feb; 16(1):86-9. PubMed ID: 22297012
[TBL] [Abstract][Full Text] [Related]
15. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Argyriou AA; Iconomou G; Kalofonos HP
Blood; 2008 Sep; 112(5):1593-9. PubMed ID: 18574024
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Broyl A; Corthals SL; Jongen JL; van der Holt B; Kuiper R; de Knegt Y; van Duin M; el Jarari L; Bertsch U; Lokhorst HM; Durie BG; Goldschmidt H; Sonneveld P
Lancet Oncol; 2010 Nov; 11(11):1057-65. PubMed ID: 20864405
[TBL] [Abstract][Full Text] [Related]
18. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Hsiao SC; Wang MC; Chang H; Pei SN
Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.
Jagannath S; Barlogie B; Berenson J; Siegel D; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Adams J; Kauffman M; Esseltine DL; Schenkein DP; Anderson KC
Br J Haematol; 2004 Oct; 127(2):165-72. PubMed ID: 15461622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]